购物车
- 全部删除
- 您的购物车当前为空
Anti-Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE Antibody (6C515) 是一种 Mouse 抗体,靶向 Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE。Anti-Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE Antibody (6C515) 可用于 WB,ELISA。
Anti-Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE Antibody (6C515) 是一种 Mouse 抗体,靶向 Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE。Anti-Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE Antibody (6C515) 可用于 WB,ELISA。
产品描述 | Anti-Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE Antibody (6C515) is a Mouse antibody targeting Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE. Anti-Varicella-zoster virus (VZV)/HHV-3 Glycoprotein E/gE Antibody (6C515) can be used in WB,ELISA. |
Ig Type | Monoclonal Mouse IgG1 |
克隆号 | 6C515 |
验证活性 | Anti-VZV / HHV-3 gE / glycoprotein E mouse monoclonal antibody in 1 μg/mL. -Sample: Recombinant Protein 10 ng -Lane A: VZV / HHV-3 gE / glycoprotein E Protein -Lane B: VZV (strain Oka vaccine) Glycoprotein B Protein -Lane C: VZV (strain Oka vaccine) gH & gL Heterodimer Protein -Secondary -Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution. -Developed using the ECL technique. -Performed under reducing conditions. |
应用 | WB,ELISA |
推荐剂量 | WB: 0.2-1 μg/mL; ELISA: 0.5-1 μg/mL |
抗体种类 | Monoclonal |
宿主来源 | Mouse |
构建方式 | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Varicella-zoster virus (VZV) / HHV-3 gE / glycoprotein E (40907-V08HQ9J3M8Met1-Tyr538). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
纯化方式 | Protein A |
性状 | Liquid |
缓冲液 | 0.2 μm filtered solution in PBS |
偶联 | Unconjugated |
免疫原 | Recombinant Varicella-zoster virus (VZV) / HHV-3 gE / glycoprotein E Protein (TMPY-06357) |
抗原种属 | VZV |
储存方式 | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
运输方式 | Shipping with blue ice. |
评论内容